Focal Epilepsy

Purpose of Study:  To evaluate the efficacy, safety, and tolerability of an investigational drug as adjunctive therapy in subjects with Refractory Partial seizures.

Inclusion Criteria:

• Age 16+
• Diagnosed with Epilepsy for at least 1 year with partial seizures
• CT or MRI within past 5 years
• History of inadequate response to at least 1 AED
• Current treatment with 1 to 2 approved antiepileptic drugs and taking a stable dose of the same AED(s) for two months prior to screening
• Vagal nerve stimulator (VNS) is not considered as a concomitant AED
• No seizure-free period for more than 3 weeks

Exclusion Criteria:

• History of alcohol or drug abuse
• Progressive neurological disorder, such as a brain tumor, demyelinating disease, and degenerative CNS disease
• History of status epilepticus, primary generalized seizures, clustering or nonepileptic seizures including psychogenic seizures
• History or current serious or medically unstable systemic disease such as liver disease, renal insufficiency, etc.
• Current or past (within 1 year) major psychotic disorder such as schizophrenia, bipolar disorder, etc.
• Planned epilepsy surgery within the next 6 months
• Currently on ketogenic diet
• History of prior exposure to the study medication
• Received retigabine in previous study
• Treated with felbamate or vigabatrin in the past 6 months
• History of primary generalized seizures

If you qualify, all study related care is provided at no charge including:

• Study visits and study related procedures/tests
• Laboratory tests
• Study drug
• Reimbursement for time/travel expenses

Inclusion/Exclusion Criteria Must Be Met